adplus-dvertising
Connect with us

Live Business Updates

SINOVAC’s COVID-19 Vaccine Receives Emergency Use Authorization in Brazil for Children Aged 3-5 Years

Published

on

BEIJING-July 14, 2022–(BUSINESS WIRE)–Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading Chinese supplier of biopharmaceutical products, announced that its COVID-19 vaccine (CoronaVac) was approved by Brazil’s National Health Surveillance Agency, Anvisa, on July 13 Emergency admission for children between 3 and 5 years old. Children in this age group receive the same dose as children aged 6 to 17 years and adults. There is no restriction on use in immunocompromised children aged 3 to 5 years.

This approval was granted on the basis of comprehensive evaluations based on the analysis of all available data on the vaccine and its use in children. The analysis was based on data from the Instituto Butantan, on research data from Chile, where the vaccine is already being used in this age group, on research results on the Covid-19 vaccination in Brazil, on opinions from invited medical societies, on real-world findings and on data from scientific publications.

The SBP (the Brazilian Association of Paediatricians), the SBI (the Brazilian Society of Infectious Diseases), the SBPT (the Brazilian Society of Pneumology and Phthisiology), the SBIm (the Brazilian Society of Vaccination) and Abrasco took part in this evaluation (the Brazilian Association for Collective Health). In order to be able to support the Anvisa health authority in evaluating the vaccine, the experts from the institutes mentioned had access to specialist materials and research data on the vaccine.

The CoronaVac vaccine has been approved in Brazil for the emergency treatment of adults since January 17, 2021. As a result, on January 20, 2022, Anvisa approved the extension of vaccine use to children and adolescents aged 6 to 17 years.

As of July 14, 2022, CoronaVac has been approved for emergency treatment of minors in 14 countries and regions including Chile, Colombia, Ecuador, Brazil and various countries and regions in Asia and Africa.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company focused on the research and development, manufacturing and commercialization of vaccines that protect against human infectious diseases.

SINOVAC’s product portfolio includes vaccines against COVID-19, hand, foot, and mouth disease (HFMD) caused by enterovirus 71 (EV71), hepatitis A and B, seasonal flu, pneumococci, pandemic flu H5N1 (bird flu), the flu H1N1 (swine flu), against varicella (chicken pox), mumps and poliomyelitis (poliomyelitis).

The COVID-19 vaccine CoronaVac® is approved for use in more than 60 countries and regions worldwide. The vaccine Healive® against hepatitis A met the requirements of the WHO prequalification in 2017. The innovative EV71 vaccine Inlive® has been on the market in China since 2016. In 2022, SINOVAC’s inactivated polio vaccine from Sabin strains (sIPV) received WHO prequalification.

SINOVAC was the first company to receive approval for its H1N1 flu vaccine, Panflu.1®, which powered the Chinese government’s vaccination campaign and stockpiling program. It is the only company supplying the Panflu® vaccine against the pandemic H5N1 flu for the Chinese government’s stockpiling program.

SINOVAC is continuously researching and developing new vaccines, has further combination vaccines in the pipeline and is constantly exploring global market opportunities. SINOVAC intends to expand and deepen trade and cooperation with other countries as well as with business and industry associations.

For more information, visit the company’s website at www.sinovac.com.

The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. Therefore, compare translations with the original language version of the publication.

View original version on businesswire.com: https://www.businesswire.com/news/home/20220714005373/en/

Contacts

Sinovac Biotech Ltd.
PR team
[email protected]

ICR Inc.
Bill Zima
Tel. USA: 1-646-308-1707
[email protected]

Source: de.finance.yahoo.com

WATCH NOW

DOWNLOAD NOW

Spread the love
Click to comment

Leave a Reply

Your email address will not be published.